Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): A Nationwide Snapshot of the Status of Treatment for Major Depression
Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): A Nationwide Snapshot of the Status of Treatment for Major Depression
复制标题
DOI：
10.1055/s-0034-1375628
复制
发表时间：
2014-05-01
影响因子：
4.3
通讯作者：
Mencacci, C.
中科院分区：
文献类型：
--
作者：
Aguglia, E.;Biggio, G.;Mencacci, C.
简介： 重度抑郁症是一个世界性问题，并且常常未被发现和治疗。鉴于检测率低且需要在短时间内进行干预，确定可能改善治疗结果的因素非常重要。方法：STIMA-D 旨在提供意大利重度抑郁症患者的概况（重点关注护理途径、患者特征、药物治疗和治疗结果）。入组患者（男/女，年龄在 18 至 65 岁之间）经历过单次/多次重度抑郁发作 (DSM-IV-TR)。排除了终生或当前患有双相情感障碍或其他精神障碍的患者。结果：50 个受邀中心中有 44 个中心发送了涉及 1 140 名患者的数据。大多数患者是女性。在上班族中，52.5%的人在过去6个月内因抑郁症缺勤。重度抑郁症的反复发作非常常见，并且与残留的发作后症状的持续存在、情绪障碍家族史和焦虑的存在有关。 59.6%的患者接受单一疗法（SSRI或SNRI），而其中19.2%的患者接受SSRI加SNRI治疗。单一治疗中只有 25.5% 的患者获得完全缓解，而双重治疗的患者只有 12.4% 获得完全缓解。讨论：重性抑郁症的不良结局对患者的生活质量和费用负担具有深远的影响。因此，迫切需要具有新颖作用方式的新药理学方法。
Introduction: Major depression is a worldwide problem and often remains undetected and untreated. Given the low rates of detection plus the need to intervene in a short time, it is important to identify factors which are likely to improve treatment outcomes.Methods: STIMA-D was designed to provide the profile of patients with major depression in Italy (focusing on pathway to care, patient characteristics, drug therapy and treatment outcomes). The patients enrolled (M/F, aged between 18 and 65) experienced single/multiple episodes of major depression (DSM-IV-TR). Patients with lifetime or current bipolar syndrome or other mental disorders were excluded.Results: 44 of the 50 invited centers sent data concerning 1 140 patients. The majority of patients were women. Among working individuals, 52.5% of them were absent from work due to depression in the previous 6 months. Recurrent episodes of major depression were very common and were associated with persistence of residual post-episodic symptoms, a family history of mood disorders and presence of anxiety. 59.6% of the patients were treated with monotherapy (SSRI or SNRI), while 19.2% of them were treated with SSRI plus SNRI. Only the 25.5% on monotherapy had a complete response compared to 12.4% of patients on dual therapy.Discussion: Poor outcomes in major depression have profound implications on patients' quality of life and cost burden. New pharmacological approaches with novel modes of action are therefore urgently needed.